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Objective. This study aimed to investigate the bacterial population in patients with medication-related osteonecrosis of the jaw
(MRONJ) after treatment with doxycycline and metronidazole.
Study Design. A total of 38 patients with MRONJ (age range 55-88, mean age 73 + 8.82 standard deviation) treated with doxy-
cycline first and with metronidazole second were enrolled in this study. Two swabs were taken at the margin of the infected
MRONJ lesion after applying pressure on the marginal mucosa, and visible pus was secreted. Real-time polymerase chain re-
action was used to analyze 20 periopathogenic and commensal species and the total bacterial level. Bacterial counts were compared
between antibiotic treatments and with a control group of orally healthy patients who didn’t have periodontal pockets of more
than 3 mm (n = 29) by means of a Mann-Whitney U test. Comparisons between the two antibiotic treatments were performed
by a paired Wilcoxon signed rank test.
Results. The total bacterial level was significantly higher in the MRONJ patients treated with systemic antibiotics compared with
the control group. However, significant lower bacterial amounts were found for 12 of the 20 investigated bacteria. We couldn’t
establish a significant advantage of metronidazole administration after doxycycline treatment.
Conclusion. Our findings suggest that the total bacterial level in MRONJ patients is higher even when treated with systemic
antibiotics. The significantly different bacterial amounts of the selected species suggest an alteration in the microbial population.
(Oral Surg Oral Med Oral Pathol Oral Radiol 2017;■■:■■–■■)
Infection is believed to play an important role in the patho-
genesis of medication-related osteonecrosis of the jaw
(MRONJ), and recently studies have reported bacterial
colonization of affected bone in MRONJ.1-5
Patients may be considered to have MRONJ if all the
following characteristics are present: current or previ-
ous treatment with antiresorptive or antiangiogenic agents,
exposed bone or bone that can be probed through an in-
traoral or extraoral fistula in the maxillofacial region that
has persisted for longer than 8 weeks, and no history of
radiation therapy to the jaws or obvious metastatic disease
to the jaws.6 MRONJ involves the maxilla and mandi-
ble with preference for the mandible.7 MRONJ adversely
affects quality of life, producing significant morbidity.
There are multiple risk factors, such as tooth extrac-
tion, diabetes, tobacco use, trauma to oral tori or caused
by prosthetic appliances, poor oral hygiene, malnutri-
tion and bone manipulation.8-11
Route of administration, type of medication and treat-
ment duration are other important risk factors.6,7
Infection naturally follows on the bone exposed to the
microbial flora of the oral cavity. Almost all the MRONJ
specimens are colonized with microbial biofilms.2,4,9
Despite the fact that they are routinely exposed to oral
microorganisms that consist of more than 750 bacteria,
the jaws are normally resistant to colonization. Conse-
quently, for colonization to take place, it is needed to have
a combination of patient susceptibility and the pres-
ence of potentially pathogenic microorganisms.3,12
The source could be the spread of odontogenic or peri-
odontal infection. Microbial biofilms associated with teeth
and periodontium that gain access to the underlying com-
promised bone may play a critical role in the pathogenesis
of MRONJ lesions.13-15 Bone exposure during surgery or
tooth extraction works as a trigger that opens the door
for bacterial invasion. This could explain the strong re-
lationship between MRONJ and dental surgery.
Furthermore, the higher sensitivity of jaws to infection,
compared with other bones, strengthens this hypothe-
sis. Jawbones come in direct contact with the external
environment because of the fine layer of overlying
mucosa, nonstop exposure to trauma, and presence of
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Statement of Clinical Relevance
This line of investigation will be critical in the future
for clinical approaches to disease intervention and for
targeted antimicrobial therapeutics in patients with
medication-related osteonecrosis of the jaw.
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patients who are receiving chemotherapy, including im-
munosuppressants and corticosteroids, which give greater
susceptibility to dental infection. Furthermore, medical
comorbidities such as diabetes are found in MRONJ pa-
tients, and studies have reported a direct correlation with
chronic periodontitis and impaired wound healing, leading
to bacteria-induced bone loss.17,18
A biofilm is a complex community of sessile bacte-
rial and fungal organisms attached to a surface. Biofilm
organisms differ substantially from their free-floating
counterparts because they are characterized by a com-
munity of cells that are attached to a substrate. They are
enclosed in a matrix of extracellular polymeric sub-
stances that they have produced to connect to and to
communicate with each other and with the environ-
ment. Additionally they display an altered phenotype
regarding growth rate, gene transcription, and antimi-
crobial resistance.3,19 A microbial biofilm applies chemical
communication using signaling molecules named quorum
sensing compounds as well as electrical communica-
tion via nanowires.5,20,21 Microbial biofilms are thought
to play a part in the pathogenesis of 65%-80% of all
chronic infections.4 Complex mixed-species biofilms
have been reported and studied in many diseases, in-
cluding dental caries, chronic periodontitis, and apical
periodontitis.14,15 Even though the presence of bacterial
biofilms may not directly induce necrosis, it seems to have
an important contributing role in MRONJ.
The clinical problem with MRONJ is a chronic mi-
crobial biofilm infection of bone, in the context of
antiresorptive or antiangiogenic agents.5
Classic methods of screening and culturing for infec-
tious disease commonly miss biofilm bacteria because
these techniques are based on planktonic bacterial growth.
Oral bacteria have evolved over millions of years in mixed
biofilm populations, and these organisms are often
unculturable. Additionally, cultures from the oral cavity
have high rates of contamination, and exposure to oxygen
kills a lot of the anaerobic bacteria. Biofilm identifica-
tion requires direct visualization methods with advanced
microscopy or DNA-and RNA-based techniques.5
One of the central studies that supports the concept
that bone containing bisphosphonates is more sensitive
to bacterial colonization was performed by Ganguli et al.17
who reported that bacterial adhesion to pamidronate-
coated hydroxyapatite (HA) was 60-fold greater than
uncoated HA and 90-fold greater than clodronate-
coated HA. Because clodronate is a chlorine-based
bisphosphonate and not a nitrogen-based compound like
pamidronate or most other bisphosphonates, these data
suggest that the nitrogen moiety of the bisphosphonate
compound may play a role in the pathogenesis of
MRONJ. The structure of these bisphosphonate com-
pounds could play an important role in the disease process
of MRONJ.18
Initially it was thought that osteonecrosis was
bisphosphonate related, but recently there have been
reports of MRONJ with denosumab, a RANKL anti-
body and very strong antiresorptive.22,23 These findings
not only expand the list of drugs associated with MRONJ,
they change our views on the pathophysiology of this
chronic disease. Although they have different mecha-
nism of action, denosumab and bisphosphonates both
reduce the rate of bone loss, an effect that might be crucial
in the etiology of MRONJ.
Several pathogenic bacteria found in the oral cavity
can invade jawbones and cause bone destruction through
different direct and indirect mechanisms. There are many
suggested mechanisms, including direct damage to the
noncellular bone matrix by bacterial acids and prote-
ases, interaction of bacterial factors directly with bone
cells, or indirectly through inflammatory agents, result-
ing in bone degradation and impairment of bone formation
processes. Another mechanism is the invasion of osteo-
blasts by bacteria, producing functional disturbances and
apoptosis, leading to inhibition of bone remodeling.24 Bac-
terial chemical mediators of bone resorption consist of
proteins such as porins and collagen-degrading enzymes,
by which they obtain fundamental amino acids for growth
or create an anaerobic environment in the bone for further
growth and spread.25,26
Infection playing an important role in the pathogen-
esis of MRONJ could imply the need for more rational
antibiotic therapy, with an efficient system of applica-
tion of antibiotics to the hypovascular and hypocellular
bone. That is, it should be taken into account that sys-
temic antibiotic therapy may have a limited effect on the
bacterial population associated with MRONJ lesions.16
Here, we report the total bacterial level and the amount
of selected oral bacterial phylotypes that colonize the
jawbone of stage 2 and stage 3 MRONJ patients treated
with systemic antibiotics and antimicrobial rinses. We
also investigate the advantage of metronidazole admin-
istration after doxycycline treatment. We used real-
time polymerase chain reaction (RT-PCR) analyses for
20 selected periopathogenic and commensal species.
MATERIAL AND METHODS
Sample collection
The study received approval from the Ethical Commit-
tee of the University Hospitals of the Catholic University
of Leuven (S57399), was registered in the Institutional
Clinical Trials database, and was conducted according
to the ICH-GCP (International Conference on Harmo-
nization Guidelines on Good Clinical Practice) principles
and Helsinki guidelines. The study took place in 2015.
A total of 38 patients (male and female) with a history
of intravenous bisphosphonate or denosumab therapy and
bone exposure in the oral cavity for more than 8 weeks,
as per the definition of MRONJ, were recruited for this
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study. Only patients with stage 2 or 3 MRONJ lesions
were included. Exclusion criteria were (1) any history
of radiation therapy to the head and neck region and (2)
obvious metastatic disease of the jaws. Written in-
formed consent was obtained from all the 38 patients
selected for this study. All the patients were treated with
an oral antimicrobial rinse (chloramine 0.5% dissolved
in water) in combination with oral antibiotic therapy. Two
swabs were taken at the margin of the infected MRONJ
lesion after applying pressure on the marginal mucosa,
and visible pus was secreted. There were no periodon-
tal conditions in this patient group. The first swab was
taken after at least 2 weeks of doxycycline therapy
(100 mg once a day) and the second swab was taken after
2 weeks of metronidazole therapy (500 mg three times
a day). We were unable to take a second swab from seven
patients who were lost to follow-up. All samples were
used for RT-PCR analyses for 20 selected periopathogenic
and commensal species (n = 38 for the doxycycline group;
n = 31 for the metronidazole group). As control group,
the database of Loozen et al.27 with the microbiologic
analyses of untreated healthy patients was used. Sub-
gingival plaque samples were taken by dental clinicians
with access to case history, radiographs, and clinical data.
Clinicians had a choice to take between 1 and 5 samples
using sterile paper points. These paper points were de-
posited into marked Eppendorf tubes and sent at room
temperature for RT-PCR analyses for the 20 selected
pathogenic and commensal species. The control group
consisted of patients who didn’t have pockets of
more than 3 mm; these patients weren’t treated with an-
tibiotics and didn’t have MRONJ (n = 29 for control
group). The oral flora in these shallow pockets was con-
sidered to be equal to the normal oral flora in healthy
patients.
DNA extraction and RT-PCR
After taking the swabs, samples were transported at room
temperature to Advanced Dental Diagnostics B.V.
(Malden, the Netherlands). DNA from the samples was
obtained using the Quickextract DNA extraction
(Epicentre Biotechnologies, Madison, WI, USA) accord-
ing to the manufacturer’s instructions. We used RT-
PCR analyses for 20 selected oral bacteria. The bacterial
profile was determined by RT-PCR by 16 S rRNA gene
fragments. The targets were detected by using TaqMan
probes (Table I). Total and individual levels of selected
periopathogenic and commensal species (n = 20) were
calculated. This analysis provides information of both the
quantity (total bacterial level) and the quality (compo-
sition) of the biofilm. The original microbial data were
converted to log10 values. The total amount of bacteria
and the relative presence of the different bacteria were
calculated.
Statistical analyses
Bacterial counts were log10 transformed before analy-
sis. To be able to deal with zero counts, the log10
transformation was taken from the bacterial count + 1.
Bacterial counts were compared between antibiotic
treatments and with a control group of patients who didn’t
have periodontal pockets of more than 3 mm by means
of a Mann-Whitney U test. Comparisons between the two
antibiotic treatments were performed by a paired Wilcoxon
signed rank test.
Antibiotic treatments were also compared with each
other with respect to absence or presence of the various
bacterial species by means of a generalized linear mixed
model for binary data with patient as random factor. Com-
parisons with the group of patients who didn’t have
pockets of more than 3 mm were performed by means
of a generalized linear model for binary data. Each time,
a logit link was applied. Comparisons between antibi-
otic treatments and the group of shallow pockets were
corrected for simultaneous hypothesis testing accord-
ing to Sidak. Statistical significance was accepted at P
values < .05.
RESULTS
The study included 20 men and 18 women. The age range
was 55-88, the mean age was 73 + 8.82 standard devi-
ation (SD). Six patients were treated for osteoporosis and
32 patients were treated for cancer; 20 patients were
treated with intravenous (IV) bisphosphonates, 10 pa-
tients received denosumab, and 8 patients had a history
Table I. List of oral bacteria
Abbreviation Genus and species
Aa Aggregatibacter actinomycetemcomitans
Pg Porphyromonas gingivalis
Tf Tannerella forsythia*
Td Treponema denticola
Pi Prevotella intermedia
Fn Fusobacterium nucleatum
Pm Parvimonas micra†
Pn Prevotella nigrescens
Cg Campylobacter gracilis
Cr Campylobacter rectus
En Eubacterium nodatum
Ec Eikenella corrodens
Cs Capnocytophaga species
Cc Campylobacter concisus
Smg Streptococcus mitis group
Sg Streptococcus gordonii
Sc Streptococcus constellatus
Ao Actinomyces odontolyticus
Av Actinomyces viscosus
Vp Veillonella parvula
*Previously Tannerella forsythensis.
†Previously Peptostreptococcus micros.
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of treatment with the combination of IV bisphosphonates
and denosumab (Table II).
Total bacterial level
There were was a significant difference in the total bac-
terial count of the doxycycline (mean 8.256 ± 0.932 SD)
and metronidazole (mean 8.29 ± 0.909 SD) samples in
the MRONJ patients compared with the control group
of healthy patients who didn’t have pockets of more than
3 mm (mean 6.659 ± 1.364 SD). The total bacterial level
was significantly higher in the MRONJ patients treated
with these antibiotics (Figure 1).
Doxycycline treatment
Significant lower bacterial amounts were found for
Aggregatibacter actinomycetemcomitans (Aa), Treponema
denticola (Td), Prevotella intermedia (Pi), Fusobacte-
rium nucleatum (Fn), Capnocytophaga species (Cs),
Streptococcus mitis group (Smg), Streptococcus gordonii
(Sg), Actinomyces odontolyticus (Ao), Actinomyces
viscosus (Av), and Veillonella parvula (Vp) in the doxy-
cycline group compared with the control group (P < .0002,
P < .0001, P < .002, P < .0001, P < .0001, P < .002,
P < .0001, P < .0001, P < .0001, and P < .0002,
respectively).
Metronidazole treatment
Significant differences were found for Aa, Tannerella for-
sythia (Tf), Td, Pi, Fn, Campylobacter gracilis (Cg), Cs,
Smg, Sg, Streptococcus constellatus (Sc), Av, and Vp
between the metronidazole group and the control group
(P < .0004, P < .02, P < .0001, P < .001, P < .0001,
P < .0001, P < .0001, P < .003, P < .004, P < .0001 and
P < .0001, respectively). Significantly lower amounts were
found for all these bacteria except for Sc, where a sig-
nificantly higher amount was found in the metronidazole
group.
Differences between doxycycline and
metronidazole treatment
Comparisons between the 2 antibiotic treatments were
performed by a paired Wilcoxon signed rank test. Sig-
nificant differences between the doxycycline and
metronidazole groups were found for Fn, Cg, and Ao.
Significantly lower amounts of Fn and Cg were found
in the group treated with metronidazole compared with
the doxycycline group (P < .04 and P < .005, respec-
tively). However, significantly higher amounts of Ao were
found in the metronidazole group compared with the pa-
tients treated with doxycycline (P < .04). No significant
differences were noted between doxycycline and met-
ronidazole treatment for the other selected bacteria
(Figure 2).
Comparison of absence or presence of
bacterial species
Antibiotic treatments were also compared with each other
and with the control group with respect to absence or pres-
ence of the various bacterial species by means of a
generalized linear mixed model for binary data with
patient as random factor. The presence in the samples
was significantly less for the group treated with doxy-
cycline compared with the control group for Aa, Td, Pi,
Cs, Smg, Sg, and Av (P < .02, P < .0002, P < .01,
P < .0004, P < .003, P < .01, and P < .0002, respective-
ly). Furthermore, a significant lower incidence of Aa, Td,
Pi, Cs, Smg, Sg, Av, and Vp was also found in the group
Table II. Demographic and clinicopathologic features
of study patients
Number
Age
(2015) Gender
Illness Requiring
ONJ-Inducing
Medication
ONJ-Inducing
Medication
1 80 F Osteoporosis BP
2 76 F Multiple myeloma BP
3 75 M Osteoporosis BP
4 60 M Renal cancer BP + Denosumab
5 83 M Multiple myeloma BP
6 68 F Breast cancer Denosumab
7 75 F Multiple myeloma BP
8 64 F Multiple myeloma BP
9 74 F Breast cancer Denosumab
10 79 M Prostate cancer BP
11 65 F Breast cancer Denosumab
12 88 F Breast cancer BP
13 81 F Osteoporosis BP + Denosumab
14 80 F Renal cancer BP + Denosumab
15 71 F Osteoporosis Denosumab
16 79 F Breast cancer BP
17 66 M Multiple myeloma BP
18 67 M CML BP
19 77 M Multiple myeloma BP
20 65 F Multiple myeloma BP
21 88 M Prostate cancer Denosumab
22 59 F Breast cancer BP + Denosumab
23 64 F Osteoporosis BP
24 70 M Prostate cancer BP + Denosumab
25 55 M Stomach cancer Denosumab
26 69 M Prostate cancer Denosumab
27 60 M Renal cancer Denosumab
28 82 M Multiple myeloma BP
29 82 M Renal cancer and
prostate cancer
BP + Denosumab
30 81 M Prostate cancer Denosumab
31 84 M Prostate cancer BP + Denosumab
32 67 F Breast cancer BP
33 73 M Multiple myeloma BP
34 64 F Osteoporosis BP
35 84 F Multiple myeloma BP
36 80 M Prostate cancer BP
37 62 M Lung cancer BP
38 77 M Prostate cancer Denosumab
BP, bisphosphonates; CML, chronic myeloid leukemia; ONJ, osteo-
necrosis of the jaw.
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treated with metronidazole compared with the control
group (P < .03, P < .0002, P < .01, P < .0006, P < .01,
P < .01 P < .0004, and P < .05, respectively).
Antibiotic treatments were also compared with each
other with respect to absence or presence of the various
bacterial species (Figure 3). There was a significant lower
incidence of Tf, Fn, Eubacterium nodatum (En), Sc, and
Av in the metronidazole group compared with the group
treated with doxycycline (P < .02, P < .0001, P < .0001,
P < .02, and P < .002, respectively).
DISCUSSION
The paucity of investigation into the role of oral bacte-
ria in the pathogenesis of MRONJ has hindered proper
disease characterization and treatment. There are many
hypotheses on MRONJ pathogenesis such as remodel-
ing suppression that allows accumulation of nonviable
osteocytes, direct cytotoxic effect on osteocytes,
antiangiogenic effects, and the role of oral bacteria.8
Factors such as dental infections, trauma, and invasive
procedures act as initiators of MRONJ.28 It is known that
several species of bacteria can cause alveolar bone de-
struction by their products (e.g., lipopolysaccharides).25
It is not known whether bacteria promote the lesion, or
whether they colonize the MRONJ lesion after it has de-
veloped. This study using 16 S rRNA culture-independent
molecular methods determined the bacterial profile of
MRONJ patients treated with systemic antibiotics. We
found a significantly higher total bacterial count in
the MRONJ patients treated with doxycycline and
metronidazole compared with a control group of healthy
untreated patients.
Aggregatibacter actinomycetemcomitans is consid-
ered as an opportunistic pathogen and has been reported
to be associated with periodontal disease and osteomy-
elitis, as well as MRONJ.1,2,29 Most of these assumptions
are based only on microscopic observations. We used
molecular 16 S rRNA gene techniques, with RT-
PCR analyses, but did not observe Aggregatibacter
actinomycetemcoitans.
When comparing our results to the color-coded biofilm
complexes described by Socransky et al.,30 we found that
the red complex pathogenic anaerobic bacteria (Tf, Td,
and Porphyromonas gingivalis [Pg]) didn’t have a clear
association with disease in our study.27 On the contrary,
significantly lower bacterial amounts of Td were found
in patients treated with doxycycline and significantly lower
amounts of Tf and Td were found in the metronidazole
treatment group. Additionally, our study also found a
lower prevalence of Pi, Fn, and Cg. These bacteria are
members of the orange complex bacteria, which was re-
ported to be strongly correlated with the red complex and
with disease in the study of Socransky et al.30 Different
bacteria displayed a decreased abundance in our study:
Fig. 1. Total bacterial level in the medication-related osteonecrosis of the jaw patients treated with doxycycline and metronida-
zole and in the control group.
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Cs, Smg, Sg, Sc, Av, Ao, and Vp. These species groups
have been defined as non–disease associated, situated in
the green, yellow, or purple complexes.
This finding suggests an alteration in the microbial pop-
ulation. Although all the MRONJ patients in our study
had clinical signs of infection, we did not find high
numbers of periodontal pathogens such as Pg, Tf, and
Td.
Cancer patients are more susceptible to infection
because they are immunocompromised and have reduced
regenerative capability, whereas osteoporotic patients have
disturbed levels of bone regeneration.31 Osteoporotic pa-
tients often suffer from other chronic diseases and have
increased risk of developing opportunistic infections,
which may relate to reduced bone mineral density and
alveolar bone loss, premature teeth loss, and increased
severity of periodontal diseases.1,32
Metronidazole is one of the most commonly indi-
cated antibiotics for the treatment of periodontal disease.2
However, we couldn’t find an advantage of metronida-
zole administration after doxycycline treatment in patients
with stage 2 MRONJ. It is well established that the long-
term use of antimicrobials might eradicate normal flora,
which induces an imbalance in microbial composition.5
A limitation of the study is that only 20 oral bacteria are
examined. Because the oral cavity can harbor more than
1000 microorganisms, other bacteria can also play a
crucial role. However, the 20 bacteria investigated in the
present study are all key bacteria in the oral environ-
ment and have proven to play a crucial role in the oral
cavity.30 Additionally, metagenomic identification of bac-
teria determines the presence of specific DNA but not
viability; because bacterial DNA can remain PCR de-
tectable for up to 1 year after cell death, metagenomics
may overestimate current bacterial load.33 Further, a single
microbiologic examination cannot determine if specific
bacteria are permanent or transient residents or are primary
pathogens or merely bystanders to disease.
Our study using 16 S rRNA molecular technique in-
dicates an alteration in the microbial population of
MRONJ patients treated with systemic antibiotics.
However, we did not compare these results with un-
treated MRONJ patients because of the ethical problems
with not treating patients. No significant advantage was
identified for metronidazole administration after doxy-
cycline treatment. These findings require further evaluation
with larger participant populations and more oral mi-
croorganisms have to be examined. Continuing in this
line of investigation will be critical in the future for clin-
ical approaches to disease intervention and for targeted
antimicrobial therapeutics.
The authors are grateful to professor W. Teughels and Ad-
vanced Dental Diagnostics B.V. for providing the microbiologic
data set on which analysis was performed.Fi
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Fig. 3. Bacterial species with significant different counts in medication-related osteonecrosis of the jaw patients treated with doxycycline and metronidazole compared with the control
group.
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